# Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

> **NCT03100253** · PHASE4 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 208 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Etanercept
- **DRUG:** Infliximab
- **DRUG:** Adalimumab
- **DRUG:** Golimumab
- **DRUG:** Certolizumab Pegol

## Key facts

- **NCT ID:** NCT03100253
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 208 (ACTUAL)
- **Why stopped:** Slow recrutiment
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100253, "Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03100253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*